NJ-PHARMABCINE-INC.
PharmAbcine Inc., a clinical-stage biotech company developing novel antibody therapeutics for multiple cancer indications, announces it has entered into a collaborative agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA), through a subsidiary, to evaluate PharmAbcine’s anti-VEGFR2 mAb, TTAC-0001, in combination with MSD’s anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients with recurrent glioblastoma multiforme (rGBM) and metastatic triple-negative breast cancer (TNBC).
PharmAbcine’s lead candidate TTAC-0001, an investigational therapy, is a highly selective and potent anti-VEGFR2 (KDR/flk-1) mAb in clinical development for rGBM indications. VEGFR2 is over-expressed in most malignant tumors, such as gastric, liver, non-small cell lung cancer (NSCLC), ovarian, brain, colorectal, and breast cancers and this signaling pathway is a key regulator for tumor angiogenesis. Increased understanding of the role of VEGF/VEGFR2 in the tumor microenvironment (TME) supports the rationale for evaluating TTAC-0001 in combination with KEYTRUDA.
“The combination of the anti-VEGFR2, TTAC-0001 and the anti-PD-1 therapy, KEYTRUDA in this study has the potential to build upon the responses already observed with each of these molecules as monotherapies,” said Jin-San Yoo, Ph.D., President and CEO of PharmAbcine. “There is a strong biologic rationale to combine these therapies as their complementary mechanisms of action may enhance the anti-tumor activity.”
Under the terms of the collaboration, PharmAbcine will conduct international Phase I/II studies to evaluate the potential clinical synergy of combining TTAC-0001 with KEYTRUDA.
About PharmAbcine Inc.
PharmAbcine is a leading clinical
stage biologics company that develops fully human therapeutic antibody
(mAb) and next generation multispecific antibody therapeutics based on
in-house developed novel platform, DIG-Body, PIG-Body and TIG-Body using
innovative discovery technology and excellent human resources for the
treatment of human diseases, such as cancer and inflammatory diseases.
PharmAbcine’s fully human antibody libraries and innovative selection system are our proprietary assets. PharmAbcine provides antibody generation services by using antibody library and selection systems. PharmAbcine also provides co-development opportunities with novel antibodies.
Under the collaboration with SAMSUNG MEDICAL CENTER, PharmAbcine has >300 patients derived cancer stem cell libraries and its animal model system for evaluating internal pipeline development.
Selected pipeline:
TTAC-0001(=Tanibirumab), anti-KDR neutralizing
fully human IgG with unique cross species cross reactivity has completed
its Phase IIa recurrent GBM trial in Australia in August 2017 and its
final report will be available early in 2018. Promising molecule to
combine with immune checkpoint blockade is open for out-licensing,
co-development and combination clinical trials.
PMC-001(=DIG-KT), next generation bispecific antibody neutralizing both VEGF-KDR and Angiopoietin-TIE2 pathways is superior to bevacizumab and Tanibirumab in preliminary studies. It also overcomes the Avastin resistant brain tumor growth. PMC-002, PMC-003, PMC-004 are derivative molecules from PMC-001.
PMC-201, next generation bispecific antibody neutralizing both VEGF-KDR and Notch-DLL4 pathways overcomes anti-cancer drug resistant tumor growth.
PMC-005B, Anti-EGFRviii truly specific fully human IgG with internalization property is perfect for ADC, CAR-T and CAR-NK purpose and is open for codevelopment or out-licensing.
PMC-309a-z, anti-VISTA fully human antibodies collection as either agonistic or antagonistic.
"3G-System" platform provides high performing production cell lines and we do have
PMC-901, bevacizumab biosimilar cell line with 3g/L productivity.
PMC-902,
aflibercept biosimilar cell line with >3g/L productivity.
Additional information about PharmAbcine is available through its
website,
https://www.pharmabcine.com
About rGBM
Glioblastoma multiforme (GBM) is the most common
malignant brain tumor in adults, with a median survival of less than 15
months from diagnosis and recurrences frequently within a year following
the initial treatment. Chemotherapy, radiation and surgery are the
primary initial treatments; chemotherapy and surgery may be possible for
recurrent disease, with limitations in using radiation dependent on the
site of recurrence. Avastin is approved as an active treatment option
(single agent) for patients with rGBM who have failed previous TMZ and
radiation therapy.
About TNBC
Breast cancer is the most common cancer in women
– it is estimated that more than 250,000 new cases will be diagnosed in
the US in 2017. 20% of breast cancers lack receptors for three common
hormones (estrogen, progesterone and HER2) and are thus called
triple-negative breast cancers (TNBC). Treatment options for TNBC are
limited, and despite therapy recurrences are frequent and aggressive.
Consequently, novel treatment strategies for TNBC are of high need.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180201005016/en/
Contact:
Media Contacts
For PharmAbcine:
Dr. Sung Woo Kim
sungwoo.kim@pharmabcine.com
82-42-863-2017
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MOOVE19.3.2024 09:02:26 CET | Press release
Moove secures USD $100 million Series B round
WI-CIELO19.3.2024 08:12:25 CET | Press release
Cielo Debuts First Generative AI for Talent Acquisition: CLO.ai
GALDERMA19.3.2024 07:01:34 CET | Press release
AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio
CA-NETAPP18.3.2024 23:01:28 CET | Press release
NetApp Empowers Customers to Securely “Talk to Their Data” in Collaboration with NVIDIA
KPMG18.3.2024 18:39:35 CET | Press release
KPMG’s "Digital Gateway for Tax" Platform Raises Global Standards in Tax Functionality with Generative AI
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom